Sensex Today | Nomura keeps ‘buy’ rating on Lupin, target price at Rs 2,350
#1 Received US FDA approval for gRisperdal Consta
#2 Second globally & first Indian generic approved
#3 Builds on prior approvals for gGlucagon & gVictoza
#4 Strengthens position in complex generics
Lupin was quoting at Rs 1,938.35, down Rs 13.30, or 0.68 percent.
It has touched an intraday high of Rs 1,967.95 and an intraday low of Rs 1,930.95.
It was trading with volumes of 8,231 shares, compared to its five day average of 8,727 shares, a decrease of -5.68 percent.
In the previous trading session, the share closed up 3.32 percent or Rs 62.70 at Rs 1,951.65.
The share touched a 52-week high of Rs 2,403.45 and a 52-week low of Rs 1,774.00 on 02 January, 2025 and 07 April, 2025, respectively.
Currently, the stock is trading 19.35 percent below its 52-week high and 9.26 percent above its 52-week low.
Market capitalisation stands at Rs 88,535.01 crore.